Trends in Pharmacological Sciences
Research updateVasopeptidase inhibitors: an emerging class of cardiovascular drugs
Section snippets
ACE, NEP and metabolism of hormonal peptides
Because ACE and NEP are involved in the regulation of the cardiovascular and renal systems, simultaneous inhibition of the two enzymes has the potential to reduce the activity of the renin–angiotensin system and to potentiate the vasodilatory, natriuretic and antiproliferative effects of bradykinin, natriuretic peptides and adrenomedullin (Fig. 2).
Demonstration of enhanced plasma atrial natriuretic peptide (ANP) immunoreactivity and natriuresis 7 following administration of a pure NEP inhibitor
Effects of VPIs in hypertension
VPIs have been tested on various rodent models of hypertension known to be susceptible to either ACE inhibitors or NEP inhibitors and to have different levels of plasma renin activity: models with normal renin [e.g. spontaneously hypertensive rats (SHR)] or high renin (e.g. two-kidney, one-clip Goldblatt model and sodium-depleted SHR) in which ACE inhibitors are effective, and a volume-dependent model with low renin (e.g. desoxycorticosterone acetate-sodium hypertensive rats) in which NEP (but
Effects of VPIs in heart failure
The therapeutic potential of VPIs could be even greater in heart failure 13 than in hypertension. Thus, acute administration of fasidotrilat to infarcted rats 14 or of omapatrilat to cardiomyopathic hamsters 15 lowered left ventricular end-diastolic pressure to a greater extent than pure ACE or NEP inhibitors. The effects of a four-week treatment with fasidotril on the morphological, hormonal and hemodynamic responses to myocardial infarction in rats were evaluated 14 in comparison with
Beneficial and possible detrimental effects resulting from simultaneous ACE and NEP inhibition
Globally, the rationale for simultaneous ACE and NEP inhibition is that the renin–angiotensin system and the natriuretic peptides and kallikrein–kinin system exert opposite actions on vascular tone, Na+ excretion and cell growth. However, other synergistic effects might arise from simultaneous inhibition of ACE and NEP. In a pilot study 19, administration of a NEP inhibitor in heart failure patients receiving ACE inhibitors was well tolerated, paving the way to the clinical use of VPIs.
Concluding remarks
VPIs represent a new and promising approach to the treatment of hypertension and heart failure, and preclinical studies indicate that they offer advantages over ACE inhibitors. In patients with mild to moderate hypertension, VPIs are characterized by a high response rate and seem to be particularly effective in decreasing SBP, which is now recognized to be a greater risk factor than is DBP. Organ-protective properties, related to local cGMP and nitric oxide production and possibly independent
References (26)
Sustained antihypertensive actions of a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects
Am. J. Hypertens.
(1999)The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
J. Am. Coll. Cardiol.
(2000)Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
Lancet
(2000)A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. Ecadotril Pilot Safety Study
Am. Heart J.
(1999)Plasma bradykinin in angio-edema
Lancet
(1998)- et al.
Vasopeptidase inhibition and angio-oedema
Lancet
(2000) Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation
Kidney Int.
(1991)Vasopeptidase inhibition: a new concept in blood pressure management
J. Hypertens.
(1999)Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril
Proc. Natl. Acad. Sci. U. S. A.
(1991)Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme
Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors
Exp. Opin. Ther. Patents
In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor
Hypertension
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes
J. Pharmacol. Exp. Ther.
Cited by (53)
Ring-closing metathesis/transannular cyclization to azabicyclo[X.Y.0]alkanone dipeptide turn mimics for biomedical applications
2022, Peptide and Peptidomimetic Therapeutics: From Bench to BedsideNeprilysin
2013, Handbook of Proteolytic EnzymesHuman matrix metalloproteinases: An ubiquitarian class of enzymes involved in several pathological processes
2012, Molecular Aspects of MedicineCitation Excerpt :Similarly to angiotensin-converting-enzyme (ACE), NEP inactivates ATR and thus enhances vasodilatation and natriuresis. NEP/ACE inhibitors, the so called “vasopeptidase inhibitors”, are considered a novel therapeutic approach in hypertension, heart and renal disease treatment (Bralet and Schwartz, 2001; Kenny and Stephenson, 1988). Recently, a third class of inhibitors, also including the ECE inhibitor, has been developed: the dual and triple inhibitors, in addition to their ability to effectively lower blood pressure in hypertensive patients, also display antinflammatory and antifibrotic activities.
Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors
2011, Bioorganic and Medicinal Chemistry LettersA fluorine scan of non-peptidic inhibitors of neprilysin: Fluorophobic and fluorophilic regions in an enzyme active site
2008, Journal of Fluorine ChemistryNew Insights into the Roles of Metalloproteinases in Neurodegeneration and Neuroprotection
2007, International Review of NeurobiologyCitation Excerpt :Combined with the data obtained in vivo in rodents using potent and selective NEP inhibitors, such as phosphoramidon and thiorphan (Roques et al., 1980), key roles were established for NEP in the central nervous system. Subsequently, renal NEP was shown to be the principal enzyme inactivating the vasodilator, atrial natriuretic peptide (Kenny and Stephenson, 1988), which has led to much investment in the development of NEP inhibitors, either alone or in combination with ACE inhibitors (vasopeptidase inhibitors), as drugs in the treatment of hypertension, congestive heart failure, and renal disease (Bralet and Schwartz, 2001), although concerns over their safety have been raised (Quaschning, 2005). NEP also plays important roles in other peripheral tissues such as in chemoreception and in potentiation of the response of the carotid body to hypoxia via degradation of its preferred substrate, SP (Kumar et al., 1990, 2000).